Objective The aims of this study were to assess the incidence of pancreatic cancer and the contributing factors for the diagnosis of tumors in patients with acute pancreatitis and to gain insight into how patients with acute pancreatitis should be followed up. Methods Using the electronic medical database of Shizuoka General Hospital, 177 patients admitted for acute pancreatitis in the past 6 years were evaluated retrospectively for pancreatic cancer. Results Twelve patients (6.8%) were newly diagnosed with pancreatic cancer. During the first hospitalization, 5 patients (41.7%) with a detected pancreatic mass underwent surgical treatment: the final tumor stages were IA, IIA, and IIB in 1, 2, and 2 patients, respectively. In 7 patients (58.3%) without a detected pancreatic mass at the first admission, a pancreatic mass was recognized on follow-up computed tomography (CT) in 2 patients with main pancreatic duct (MPD) dilatation, and 1 patient with recurrent acute pancreatitis. The tumor stages were IA, IIA, and IA, respectively. Among the remaining 4 patients without follow-up, the tumor stage was IV. The patient gender, age, MPD dilatation, tumor marker, and serum amylase level were not significantly associated with pancreatic cancer. The detection of a pancreatic mass on CT led to the diagnosis of pancreatic cancer. Conclusion Acute pancreatitis should be considered as a possible diagnostic indicator of pancreatic cancer. Various factors associated with acute pancreatitis and pancreatic cancer were not predictive of a diagnosis of pancreatic cancer. Only the detection of a pancreatic mass led to the early diagnosis of pancreatic cancer. Patients hospitalized for acute pancreatitis should be followed up with a diagnostic imaging modality.
Introduction
One of the factors contributing to the poor prognosis of patients with pancreatic cancer is that the condition is rarely diagnosed at an early stage. The factors that interfere with an early diagnosis include the invasive nature of examinations for pancreatic disorders, incomplete identification of risk factors associated with pancreatic cancer, and ineffective diagnostic screening.
Pancreatic cancer is one of the causes of acute pancreatitis, and acute pancreatitis due to pancreatic cancer is believed to be caused by the obstruction of the main pancreatic duct (MPD) by the tumor (1) (2) (3) (4) . Up to 2% of patients with acute pancreatitis have been reported to have pancreatic cancer (5) (6) (7) (8) (9) . In another report, a history of pancreatitis was associated with an estimated 7.2-fold increase in the risk for pancreatic cancer (10) . Furthermore, the report demonstrated a strong association between pancreatic cancer with pancreatitis diagnosed within 3 years prior and the pancreatic cancer diagnosis (10) .
In this study, we reviewed cases of pancreatic cancer in which patients were first admitted to our hospital due to acute pancreatitis. Our goal was to assess the incidence of pancreatic cancer and the contributing factors for diagnosis of the tumor in patients with acute pancreatitis, as well as to gain insight into how patients with acute pancreatitis should be followed up. 
Materials and Methods
The subjects enrolled in this study consisted of 177 patients [140 males and 37 females; mean age: 57.9±16.78 (17-89) years] admitted to our hospital for acute pancreatitis due to various causes (Table 1 ) over a 6-year period beginning in 2006.
All patients underwent a blood examination, including the determination of carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), and serum amylase levels, as well as contrast-enhanced computed tomography (CT) on admission. CT assessments included the identification of masses, MPD dilatation, and cystic lesions. When the diameter of the MPD was 3 mm or more, MPD was defined as dilated. If a mass compatible with pancreatic cancer was recognized, patients were referred for surgical treatment.
In cases where CT demonstrated pancreatic abnormalities, including MPD dilatation but no masses, the patients were followed as outpatients and repeated CT exams were scheduled every 3-6 months for one year. The patients in whom a new mass appeared on follow-up CT were re-admitted for further examination by endoscopic retrograde cholangiopancreatography (ERCP). A pancreatic-duct biopsy or brush cytology to reveal malignancy was conducted based on the ERCP findings. The patients without abnormalities were not followed up regularly by CT.
The incidence of pancreatic cancer in acute pancreatitis cases and the factors influencing the incidence, including findings on CT, were evaluated retrospectively. We defined the incidence of pancreatic cancer with acute pancreatitis as the ratio of pancreatic cancer diagnosed during the first hospitalization or after discharge among all cases of acute pancreatitis. Tumor staging was performed using the Union for International Cancer Control (UICC) TNM Classification (11) . In statistical analyses comparing patients with pancreatic cancer and those without pancreatic cancer, the factors associated with pancreatic cancer included gender, age, CA19-9 level, CEA level, serum amylase level, and the incidence of MPD dilatation on admission for acute pancreatitis. Those factors along with the tumor stage, tumor size, and diameter of MPD were statistically compared between patients diagnosed with pancreatic cancer during hospitalization and those diagnosed after discharge.
Statistical analyses were performed as follows. The patient characteristics were described using descriptive statistics and expressed as the mean and standard deviation (SD). Data comparisons between the groups were performed using the Mann-Whitney U test (two-tailed) and Fisher's exact test (two-sided). Statistical significance was recognized at p! 0.05.
Results
Among the 177 patients with acute pancreatitis, the causes of acute pancreatitis were idiopathic in 40 (22.6%), alcohol abuse in 37 (21.0%), gallstone in 34 (19.2%), acute exacerbation of chronic pancreatitis in 21 (11.9%), newly diagnosed pancreatic cancer in 12 (6.8 %), already known pancreatic cancer in 2 (1.1%), intraductal papillary mucinous neoplasm (IPMN) in 7 (4.0%), and other causes in 24 (13.6%) ( Table 1 ). In 2 of the 14 patients with pancreatic cancers, acute pancreatitis occurred during the course of chemotherapy for pancreatic cancer. Of the 177 patients, 12 (6.8%) were newly diagnosed with pancreatic cancer.
For 5 patients (Table 2) , representing 41.7% of the 12 patients with pancreatic cancer and 2.8% of the 177 patients with acute pancreatitis, a pancreatic mass was recognized on CT, and pancreatic cancer was diagnosed during the first hospitalization. The tumors occurred at the pancreatic head in 3 of the 5 patients and the MPD was dilated in 2. The other patient had a tumor at the uncinate process of the pancreatic head, and the MPD was not dilated. The diameters of the tumors were 48 mm, 15 mm, and 16 mm, respectively. The remaining 2 patients had tumors at the pancreatic body and tail and cancer at the pancreas body was accompanied with the dilatation of the upper stream of MPD and a large pseudocyst. The diameters of these 2 tumors were 23 mm and 25 mm.
All of the 5 patients underwent surgical treatment and a histopathological examination of the resected specimens, which provided conclusive evidence of pancreatic cancer. The average tumor diameter for these patients was 25.4 mm. Based on the UICC standards, the final stages of tumors were IA (1 patient), IIA (2 patients), and IIB (2 patients). To avoid pancreatitis, ERCP was not performed in any of these patients before surgery during the first hospitalization.
In the remaining 7 patients (Table 3) , representing 58.3% of the 12 patients with pancreatic cancer and 4.0% of the 177 patients with acute pancreatitis, CT during the first hospitalization did not reveal a mass. Of these 7 patients, 2 were scheduled for CT follow-up because of a dilated MPD, and pancreatic cancer was recognized at 7 and 12 months after discharge, respectively; the tumor diameter was 18 mm in one case and 41 mm in the other case. The patients underwent surgery, and histopathological diagnoses of pancreatic cancer at the final stage of IA and IIA were made. In 1 of the 7 patients, a scheduled follow-up was planned every 3 months. However, a large pancreatic cancer with a diameter of 60 mm accompanied by hepatic metastasis (stage IV) was revealed subsequent to jaundice at 2 months after discharge. The patient underwent chemotherapy after the confirmation of pancreatic cancer based on a percutaneous needle biopsy of the metastatic lesions of the liver. Of the seven patients, 4 were not followed up because the MPD was not dilated and no mass on CT was detected at the time of the first hospitalization (3 patients) or there was suspicion of chronic pancreatitis with a pseudocyst (1 patient). In 3 patients, pancreatic cancers with diameters of 35 mm, 12 mm, and 30 mm were diagnosed at 3, 9, and 24 months after discharge, respectively. Two of the 3 patients did not undergo surgery because of the tumor stage (stage IV) and the presence of hepatic metastases; instead they received chemotherapy after the confirmation of pancreatic cancer based on a percutaneous needle biopsy of the metastatic lesions of the liver. One of the 3 patients suffered from recurrent acute pancreatitis at 9 months after discharge, and a pancreatic cancer 12 mm in diameter was recognized at the pancreatic head along with a dilated MPD. Surgery was performed and a histopathological diagnosis of pancreatic cancer at the final stage of IA was made. In the remaining patient, who was not followed up because of suspicion of chronic pancreatitis, pancreatic cancer with a diameter of 22 mm was recognized at 3 months after discharge on CT, and a histopathological diagnosis of pancreatic cancer at the final stage of IV was made post-surgically. None of the factors associated with pancreatic cancer were able to predict pancreatic cancer in patients with acute pancreatitis (Table 4) . Several factors on admission for acute pancreatitis were compared between the patients in which pancreatic cancer was diagnosed during hospitalization and those diagnosed after discharge (Table 5) . No factors showed a significant difference between the two groups, while the tumor stages in the group diagnosed during the first hospitalization tended to be earlier and the serum amylase levels in the other group tended to be higher.
Discussion
Acute pancreatitis occurs due to various causes, with idiopathic cases being the most common. Pancreatic cancer is included as one of the causes (12) (13) (14) . In our study, among patients with acute pancreatitis, 12 (6.8%) had pancreatic cancer. In cases with a diagnosis of pancreatic cancer during the first hospitalization, the tumor stage tended to be early. Acute pancreatitis is a favorable indicator for pancreatic cancer at the early stage. However, pancreatic cancer was not easily diagnosed because various factors, including gender, age, MPD dilatation, tumor marker, and the serum amylase level on admission, were not significantly associated with pancreatic cancer. Only the detection of a pancreatic mass enabled the early diagnosis of pancreatic cancer, although the rate of pancreatic mass recognition at the onset of acute pancreatitis among patients with pancreatic cancer was 41.7%.
We utilized CT for diagnosing pancreatic cancer in our study. The diameters of pancreatic cancer were larger than 15 mm in almost all cases except for 1 patient with a 12-mm diameter tumor. The average tumor size did not differ significantly between the patients with pancreatic cancer diagnosed during the first hospitalization versus after discharge, probably because identifying a tumor on CT became possible only when the tumor diameter grew to more than 15 mm. These results are consistent with previous reports indicating that it is difficult to detect pancreatic tumors smaller than 15 mm by CT (15) (16) (17) (18) (19) . Nevertheless, the tumor stages detected during the first hospitalization and in the patients followed by regular examination with CT were earlier than those in the patients not followed. The fact that 6 (50%) and 3 (25%) of the 12 patients with pancreatic cancer were surgically treated at stage IIA and IA, respectively, suggests that careful observation by CT is important for the early diagnosis of pancreatic cancer. However, the limited sensitivity of CT for the detection of pancreatic cancer indicates that other imaging modalities should be considered for this purpose.
Endoscopic ultrasonography (EUS) is an alternative diagnostic method for pancreatic cancer. Several reports have described that this modality can be used to diagnose early pancreatic cancers that cannot be recognized by CT (20) (21) (22) (23) (24) (25) (26) . We suggest that EUS should be selected to diagnose pancreatic cancer at an early stage in patients with acute pancreatitis. ERCP is also an appropriate method for examining whether or not a tumor is occluding the MPD. However, because acute pancreatitis is considered to be a high-risk factor for post-ERCP pancreatitis (27-29), we chose not to proceed with this modality during the first hospitalization.
Pancreatic cancer is known to invade the MPD and obstruct pancreatic juice flow, which results in the dilatation of the duct upstream of the invaded portion and induces acute pancreatitis (1) (2) (3) (4) . MPD dilatation is an important sign of pancreatic cancer. However, our results indicate that pancreatic cancer cannot be ruled out even if the MPD is not dilated in patients with acute pancreatitis, and the induction of acute pancreatitis in patients with pancreatic cancer is not limited to invasion of the MPD and obstruction of pancreatic juice flow. Other factors, such as chemical mediators induced by pancreatic cancer, may be responsible for acute pancreatitis in the absence of MPD obstruction. When seeing patients with acute pancreatitis, it is important to pay attention to the presence of a pancreatic mass, and following up patients with acute pancreatitis after discharge is necessary, even though a pancreatic mass and dilatation of the MPD may not be evident upon CT at the onset of acute pancreatitis.
To follow up patients with acute pancreatitis postdischarge, the interval duration and the method of monitoring for tumors should be considered. We identified 1 case with a massive pancreatic head tumor and multiple liver metastases diagnosed 2 months after discharge. In another patient without planned follow-up, pancreatic cancer was diagnosed 24 months after discharge. However, these cases are exceptional and in almost all patients, cancer was diagnosed 3 to 12 months after discharge. These results suggest that performing examinations for at least 1 year after discharge is ideal. A strong association between pancreatic cancer with pancreatitis diagnosed within 3 years prior and the pancreatic cancer diagnosis was demonstrated (10) . Moreover, the risk for pancreatic cancer has been reported to be greatest in the first year after acute pancreatitis and to decrease rapidly thereafter (30) . The suggestion to perform examinations at 3-month intervals until 1 year after discharge is not discordant with the previous reports.
The incidence of pancreatic cancer in patients with acute pancreatitis was 6.8% in our study, which is higher than that of previous reports (5) (6) (7) (8) (9) . Misclassification of pancreatic cancer as pancreatitis may be responsible for the result (10). However, a recent report indicated a 12% incidence of pancreatic cancer among patients with acute pancreatitis (30) . Regardless of the exact incidence, the fact remains that a significant number of patients with acute pancreatitis will suffer from pancreatic cancer.
In conclusion, our results suggest that acute pancreatitis is a diagnostic indicator for pancreatic cancer, and the detection of a pancreatic mass on CT led to the diagnosis of pancreatic cancer, while various factors associated with acute pancreatitis and pancreatic cancer were not predictive of a diagnosis of pancreatic cancer. Moreover, patients hospitalized for acute pancreatitis should be followed up with regular examinations, including CT and EUS, if possible, for at least 1 year, even if diagnostic images do not demonstrate any pancreatic abnormalities suggestive of pancreatic cancer during the first hospitalization. However, further studies are needed to confirm our findings due to the limited number of patients included our study.
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